SEC Comment Letter 0000000000-24-006782 to RECURSION PHARMACEUTICALS, INC. (RXRX) (CIK 0001601830) (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX) (CIK 0001601830)
Date: June 13, 2024 · CIK: 0001601830 · Accession: 0000000000-24-006782
AI Filing Summary & Sentiment
File numbers found in text: 001-40323
Letter
United States securities and exchange commission logo June 13, 2024 Christopher Gibson Chief Executive Officer and Director Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 Re:Recursion Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 29, 2024 File No. 001-40323 Dear Christopher Gibson: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 13, 2024
Christopher Gibson
Chief Executive Officer and Director
Recursion Pharmaceuticals, Inc.
41 S Rio Grande Street
Salt Lake City, UT 84101
Re:Recursion Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 29, 2024
File No. 001-40323
Dear Christopher Gibson:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences